Below is a current snapshot of where retatrutide stands what the drug is, what the Phase 3 data look like, when approval is realistically expected, and what your safe options are right now
This dual benefit makes tirzepatide a promising option for individuals seeking to reduce their risk of cardiovascular disease
Semaglutide treatment offers a promising option for individuals struggling with type 2 diabetes, obesity, and cardiovascular risks
This is where supplementing glutathione to bring production levels back up comes in handy
This dual action targets the bodys metabolic pathways more comprehensively
In recent years, the FDA has begun approving GLP-1s specifically for chronic weight management to help treat obesity, as they can increase satiety, decrease hunger and result in significant weight loss